More Than Skin Clearance: Connecting Brodalumab's Mechanism of Action to Patient Outcomes in Psoriasis

Psoriasis has profound negative impacts on quality of life (QOL), including stigmatization, discrimination, occupational challenges, and mental health concerns, which are correlated with disease severity. Effective, long-term symptom control can dramatically improve the psychological and social outcomes for patients with psoriasis, though certain mechanisms of action of biologic therapies may contribute to reduced or diminished efficacy, need for treatment switching, and reduced QOL. Brodalumab is the only approved biologic indicated for moderate-to-severe plaque psoriasis that binds to interleukin-17 (IL-17) receptor A rather than targets specific IL-17 cytokines, which may contribute to its high clinical efficacy among patients who have lost responses to other biologic therapies and may also lead to sustained improvements in QOL. In biologic-experienced and biologic-naive patients, brodalumab has demonstrated optimal efficacy and improvements in QOL in both clinical trials and real-world studies, including improvements over other biologic therapies. This has the potential to dramatically improve the mental and social burdens faced by patients with moderate-to-severe psoriasis.  .